UNSPSC 51361802: Fenadiazole

This classification denotes a sedative and hypnotic with the molecular formula C8H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8YX6HIZ0IP, chemically known as 1,3,4-oxadiazole, 2-(o-hydroxyphenyl)- but generally known as fenadiazole, which bears US NIH Compound Identifier 5359546. The term FENADIAZOLE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5).

FENADIAZOLE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fenadiazole under HS 29349990 and SITC 51579. As of Q4 2014, FENADIAZOLE remains the US FDA Preferred Term for this commodity. Fenadiazole bears US NLM identifiers UMLS ID C1880747 and NCI Concept Code C65635. SMILES: C1=C/C(=C\2/NN=CO2)/C(=O)C=C1.

UNSPSC 51361802 Fenadiazole is a Commodity code that does not align with the state and local opportunities currently posted under it. The recent solicitations tagged to this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and over-the-counter products — none of which concern fenadiazole, an antiprotozoan medication with limited consumer or institutional demand. The code shows little relevant recent activity for business development purposes.

The three posted opportunities illustrate the actual pharmaceutical and health-supply procurement activity state and local agencies are conducting: Seminole County, Florida issued an IFB (60459723LAS) for naloxone and drug deactivation systems with a due date of July 26, 2023; the Texas Health and Human Services Commission posted an RFI (HHS0017013) on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. These solicitations target high-volume, high-demand medications and health supplies rather than specialty or niche pharmaceutical products. State and local buyers pursuing this code should verify that recent opportunities are genuinely tagged to fenadiazole procurement before investing sourcing effort; the current posting pattern suggests a taxonomy misalignment rather than active demand for the specified commodity.